Modulatory Effects of Curcumin and Tyrphostins (AG494 and AG1478) on Growth Regulation and Viability of LN229 Human Brain Cancer Cells

REFERENCES

• World Health Organization: Glioblastoma: Tumours of the central nervous system. Retrieved from http://www.pubcan.org/cancer/4938/glioblastoma/epidemiology
   Google Scholar
• De Witt Hamer PC: Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies. Neuro Oncol 12, 304–316, 2010.
   PubMed Web of Science ®Google Scholar
• De Witt Hamer PC: Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies. Neuro Oncol 12, 304–316, 2010.
   PubMed Web of Science ®Google Scholar
• Hart MG, Garside R, Rogers G, Stein K, and Grant R: Temozolomide for high grade glioma. Cochrane Database Syst Rev 30(4), CD007415, 2013.
   Google Scholar
• Wu W, O'Reilly MS, and Langley RR: Expression of epidermal growth factor (EGF)/transforming growth factor-A by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice. Mol Cancer Ther 6, 2652–2663, 2007.
   PubMed Web of Science ®Google Scholar
• Kisielewska J, Ligęza J, and Klein A. The effect of tyrosine kinase inhibitors, tyrphostins: AG1024 and SU1498, on autocrine growth of prostatecancer cells (DU145). Folia Histochem Cytobiol 46, 185–191, 2008.
   PubMed Web of Science ®Google Scholar
• Nicholas MK, Lukas RV, Chmura S, Yamini B, Lesniak M, et al.: Molecular heterogeneity in glioblastoma: therapeutic opportunities and challenges. Semin Oncol 38, 243–253, 2011.
   PubMed Web of Science ®Google Scholar
• Levitzki A: Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol Ther 82, 231–239, 1999.
   PubMed Web of Science ®Google Scholar
• Levitt ML and Koty PP: Tyrosine kinase inhibitors in preclinical development. Invest New Drugs 19, 213–226, 1999.
   Web of Science ®Google Scholar
• Srivastava RM, Singh S, Dubey SK, Misra K, and Khar A: Immunomodulatory and therapeutic activity of curcumin. Int Immunopharmacol 11, 331–341, 2011.
   PubMed Web of Science ®Google Scholar
• Silvestri GA and Rivera MP: Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. Chest 128, 3975–3984, 2005.
   PubMed Web of Science ®Google Scholar
• Gillies RJ, Didier N, and Denton M: Determination of cell number in monolayer cultures. Anal Biochem 159, 109–113, 1986.
   PubMed Web of Science ®Google Scholar
• Givens KT, Kirada S, Chen AK, Rorhschiller J, and Lee DA: Proliferation of human ocular fibroblasts. Invest Ophthalmol Vis Sci 31, 1856–1862, 1990.
   PubMed Web of Science ®Google Scholar
• Bojko A, Reichert K, Adamczyk A, Ligeza J, Ligeza J et al.: The effect of tyrphostins AG494 and AG1478 on the autocrine growth regulation of A549 and DU145 cells. Folia Histochem Cytobiol 5, 186–195, 2012.
   Web of Science ®Google Scholar
• Promega Corporation. Caspase-Glo® 3/7 Assay Technical Bulletin. Retrieved from https://pl.promega.com/resources/protocols/technical-bulletins/101/caspase-glo-37-assay-protocol/
   Google Scholar
• Chen X, Zhong Z, Xu Z, Chen L, and Wang Y: 2′,7′-Dichlorodihydrofluorescein as a fluorescent probe for reactive oxygen species measurement: forty years of application and controversy. Free Radic Res 44, 587–604, 2010.
   PubMed Web of Science ®Google Scholar
• Kapiszewska M, Cierniak A, Elas M, and Lankoff A: Lifespan of etoposide-treated human neutrophils is affected by antioxidant ability of quercetin. Toxicol In Vitro 1, 1020–1030, 2007.
   Web of Science ®Google Scholar
• De Witt Hamer PC: Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies. Neuro Oncol 12, 304–316, 2010.
   PubMed Web of Science ®Google Scholar
• Berezowska S and Schlegel J: Targeting ErbB receptors in high-grade glioma. Curr Pharm Des 17, 2468–2487, 2011.
   PubMed Web of Science ®Google Scholar
• Gupta SC, Patchva S, and Aggarwal BB: Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J 15(1), 195–218, 2013.
   PubMed Web of Science ®Google Scholar
• Karmakar S, Banik NL, and Ray SK: Curcumin suppressed anti-apoptotic signals and activated cysteine proteases for apoptosis in human malignant glioblastoma U87MG cells. Neurochem Res 32, 2103–2113, 2007.
   PubMed Web of Science ®Google Scholar
• Zanotto-Filho A, Braganhol E, Edelweiss MI, Behr GA, Zanin R, et al.: The curry spice curcumin selectively inhibits cancer cells growth in vitro and in preclinical model of glioblastoma. J Nutr Biochem 23, 591–601, 2012.
   PubMed Web of Science ®Google Scholar
• Senft C, Polacin M, Priester M, Seifert V, Kögel D, et al.: The nontoxic natural compound Curcumin exerts anti-proliferative, anti-migratory, and anti-invasive properties against malignant gliomas. BMC Cancer 14, 10, 491, 2010.
   Google Scholar
• Huang TY, Tsai TH, Hsu CW, and Hsu YC: Curcuminoids suppress the growth and induce apoptosis through caspase-3-dependent pathways in glioblastoma multiforme (GBM) 8401 cells. J Agric Food Chem 58, 10639–10645, 2010.
   PubMed Web of Science ®Google Scholar
• Ellis AG, Doherty MM, Walker F, Weinstock J, Nerrie M, et al.: Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase. Biochem Pharmacol 71, 1422–1434, 2006.
   PubMed Web of Science ®Google Scholar
• Carrasco-García E, Saceda M, Grasso S, Rocamora-Reverte L, Conde M, et al.: Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines. Exp Cell Res 317, 1476–1489, 2011.
   PubMed Web of Science ®Google Scholar
• Puliyappadamba VT, Chakraborty S, Chauncey SS, Li L, Hatanpaa KJ, et al.: Opposing effect of EGFRWT on EGFRvIII-mediated NF-kB activation with RIP1 as a cell death switch. Cell Rep 9, 764–775. 2013.
   Web of Science ®Google Scholar
• Frederick L, Wang XY, Eley G, and James CD: Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60, 1383–1387, 2000.
   PubMed Web of Science ®Google Scholar
• Dutta PR and Maity A: Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett 254, 165–177, 2007.
   PubMed Web of Science ®Google Scholar
• Ono M and Kuwano M: Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 12, 7242–7251, 2006.
   PubMed Web of Science ®Google Scholar
• Wang S, Guo P, Wang X, Qingyu Zhou Q, and Gallo JM: Preclinical pharmacokinetic/pharmacodynamic models of EGFR wild-type and mutant tumor models. Mol Cancer Ther 7, 407–417, 2008.
   PubMed Web of Science ®Google Scholar
• Ramis G, Thomàs-Moyà E, Fernández de Mattos SF, Rodríguez J, and Villalonga P: EGFR inhibition in glioma cells modulates Rho signaling to inhibit cell motility and invasion and cooperates with temozolomide to reduce cell growth. PLoS One 7(6), e38770, 2012.
   PubMed Web of Science ®Google Scholar
• Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J, et al.: Cytotoxic studies of paclitaxel (Taxol) in human tumor cell lines. Br J Cancer 68, 1104–1109, 1993.
   PubMed Web of Science ®Google Scholar
• Russo M, Spagnuolo C, Tedesco I, and Russo GL: Phytochemicals in cancer prevention and therapy: truth or dare? Toxins (Basel), 2, 517–551, 2010.
   PubMed Web of Science ®Google Scholar
• Sun B, Ross SM, Trask OJ, Carmichael PL, Dent M, et al.: Assessing dose-dependent differences in DNA-damage, p53 response and genotoxicity for quercetin and curcumin. Toxicol In Vitro 27, 1877–1887, 2013.
   PubMed Web of Science ®Google Scholar
• Kumar A and Bora U: Molecular docking studies of curcumin natural derivatives with DNA topoisomerase I and II-DNA complexes. Interdiscip Sci 6, 285–291, 2014.
   PubMed Web of Science ®Google Scholar
• Ketron AC and Osheroff N: Phytochemicals as anticancer and chemopreventive topoisomerase II poisons. Phytochem Rev 13(1), 19–35, 2014.
   PubMed Web of Science ®Google Scholar
• Korwek Z, Bielak-Zmijewska A, Mosieniak G, Alster O, Moreno-Villanueva M, et al.: DNA damage-independent apoptosis induced by curcumin in normal resting human T cells and leukaemic Jurkat cells. Mutagenesis 28, 411–416, 2013.
   PubMed Web of Science ®Google Scholar
• Grabowska W, Kucharewicz K, Wnuk M, Lewinska A, Suszek M, et al.: Curcumin induces senescence of primary human cells building the vasculature in a DNA damage and ATM-independent manner. Age (Dordr) 37(1), 9744, 2015.
   PubMed Web of Science ®Google Scholar
• Lewinska A, Wnuk M, Grabowska W, Zabek T, Semik E, et al.: Curcumin induces oxidation-dependent cell cycle arrest mediated by SIRT7 inhibition of rDNA transcription in human aortic smooth muscle cells. Toxicol Lett 18, 233, 227–238, 2015.
   Web of Science ®Google Scholar
• Kumar N, Yadav A, Gulati S, Kanupriya, Aggarwal N, et al.: Antigenotoxic effect of curcumin and carvacrol against parathion induced DNA damage in cultured human peripheral blood lymphocytes and its relation to GSTM1 and GSTT1 polymorphism. J Toxicol 2014, 404236, 2014.
   PubMedGoogle Scholar
• Subramanian M, Sreejayan, Rao MN, Devasagayam TP, and Singh BB: Diminution of singlet oxygen-induced DNA damage by curcumin and related antioxidants. Mutat Res 311, 249–255, 1994.
   PubMed Web of Science ®Google Scholar
• Lin HP, Kuo LK, and Chuu CP: Combined treatment of curcumin and small molecule inhibitors suppresses proliferation of A549 and H1299 human non-small-cell lung cancer cells. Phytother Res 26(1), 122–126, 2012.
   PubMed Web of Science ®Google Scholar
• Spagnuolo C, Russo M, Bilotto S, Tedesco I, Laratta B, et al.: Dietary polyphenols in cancer prevention: the example of the flavonoid quercetin in leukemia. Ann N Y Acad Sci 1259, 95–103, 2012.
   PubMed Web of Science ®Google Scholar
• Montgomery RB: Antagonistic and agonistic effects of quinazoline tyrosine kinase inhibitors on mutant EGF receptor function. Int J Cancer 10, 111–117, 2002.
   Web of Science ®Google Scholar
• Kinsella P, Howley R, Doolan P, Clarke C, Madden SF, et al. Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib. Exp Cell Res 318, 641–652, 2012.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, et al.: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21(4B), 2895–2900, 2001.
   PubMed Web of Science ®Google Scholar
• Shah BH, Nawaz Z, Pertani SA, Roomi A, Mahmood H, et al.: Inhibitory effect of curcumin, a food spice from turmeric, on platelet-activating factor- and arachidonic acid-mediated platelet aggregation through inhibition of thromboxane formation and Ca2+ signaling. Biochem Pharmacol 58, 1167–1172, 1999.
   PubMed Web of Science ®Google Scholar
• Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, and Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64, 353–356, 1998.
   PubMed Web of Science ®Google Scholar
• Dey S and Sreenivasan K: Conjugation of curcumin onto alginate enhances aqueous solubility and stability of curcumin. Carbohydr Polym 99, 499–507, 2014.
   PubMed Web of Science ®Google Scholar
• Liu J, Liu J, Xu H, Zhang Y, Chu L, et al.: Novel tumor-targeting, self-assembling peptide nanofiber as a carrier for effective curcumin delivery. Int J Nanomedicine 9, 197–207, 2014.
   PubMed Web of Science ®Google Scholar
• Bentzen PJ, Lang E, and Lang F: Curcumin induced suicidal erythrocyte death. Cell Physiol Biochem 19(1–4), 153–164, 2007.
   PubMed Web of Science ®Google Scholar
• Lang F, Gulbins E, Lang PA, Zappulla D, and Föller M: Ceramide in suicidal death of erythrocytes. Cell Physiol Biochem 26(1), 21–28, 2010.
   PubMed Web of Science ®Google Scholar
• Zappulla D: Environmental stress, erythrocyte dysfunctions, inflammation, and the metabolic syndrome: adaptations to CO2 increases? J Cardiometab Syndr 3(1), 30–34, 2008.
   PubMedGoogle Scholar